Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy
Combination therapy: sensitizing platinum-resistant tumors Carboplatin efficacy can be restored by administering it with birinapant, a drug combination that targets platinum-resistant cancer cells. Platinum-based chemotherapeutics are used to treat almost 50% of cancer patients. Despite excellent in...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2017-04-01
|
| Series: | npj Precision Oncology |
| Online Access: | https://doi.org/10.1038/s41698-017-0008-z |